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least one clopidogrel prescription (11.6%) and met inclusion cri-
teria. Mean age was 67.1 years; 65.8% were male. Commonly
recorded comorbidities included: diabetes, angina, coronary
heart disease, and hypertension. Mean length of clopidogrel
therapy was 144 days. Patterns of use analysis found 42.5% of
patients stopped therapy (deﬁned as not on clopidogrel 28 days
prior to end of follow up). A gap in therapy was seen in 82.9%
(deﬁned as late reﬁlls >14 days apart). Concomitant cardiovas-
cular drug therapies included: ACE inhibitor (34.1%), beta-
blocker (12.9%), and statin (51%). CONCLUSIONS: This
descriptive study suggests clopidogrel is substantially underuti-
lized in ACS patients. Furthermore, patients had poor long-term
adherence to therapy as demonstrated by the number who
stopped therapy or had gaps. A large gap exists between current
practice and suggested treatment guidelines.
PCV5
POTENTIAL COST SAVINGS FROM ACUTE CORONARY
SYNDROME TREATMENT IMPROVEMENTS
Klein RW1, Ohsfeldt RL2, Smolen LJ1, McCollam PL3
1Medical Decision Modeling Inc, Indianapolis, IN, USA; 2The University
of Iowa College of Public Health, Iowa City, IA, USA; 3Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVES: This research uses a Markov model of acute 
coronary syndrome (ACS) to determine the magnitudes of cost
drivers affected by new treatments. METHODS: A Markov
model was built using TreeAge Pro Healthcare and parameter-
ized to replicate the Clopidogrel in Unstable angina to prevent
Recurrent ischemic Events (CURE) trial. The model reports
results at 30 days, then every six-months over three-years for
clopidogrel plus aspirin vs. a hypothetical alternative. Reduc-
tions in risk for ﬁve events are analyzed: myocardial infarction
(MI), initial and subsequent percutaneous coronary intervention
(PCI), refractory ischemia, and stroke. Modeled risks and costs
of coronary bypass surgery and bleeding complication are not
modiﬁed. Resulting states include: no event, post each event type,
various cardiac deaths, and non-cardiac death. RESULTS: The
effects on costs of reducing relative risks of each event (and all
ﬁve together) by 10% and 20% are evaluated. Cost offsets at
one and three-years are highest for initial PCI ($239, $724;
2.0%, 2.8% of total costs for time period) for a 20% six-month
risk reduction. All other one-year offsets are less than 1.0%. Ten
percent reductions produce nearly half the cost savings. Total
savings for a 20% reduction in all ﬁve events are ($493, $1530;
4.1%, 5.8%) at one and three-years. If, instead of reducing risks
after the initial 30-day period, a 20% reduction in 30-day risk
of PTCA is modeled, then costs decrease by $389, $480, and
$616 at 30 days, one and three-years, respectively. CONCLU-
SIONS: In this model, initial PCI inﬂuences cost more than MI,
refractory ischemia, subsequent PCI, or stroke, but all are clini-
cally important. Knowing the relationship between event costs
and risk reductions can help estimate the potential cost impact
of new treatments.
CARDIOVASCULAR DISEASE—Angioplasty
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OBJECTIVES: The Clopidogrel for the Reduction of Events
During Observation (CREDO) trial showed that clopidogrel
loading prior to percutaneous coronary intervention (PCI) with
one-year treatment after PCI reduced the combined risk of death,
myocardial infarction (MI) or stroke. The purpose of this study
was to evaluate the economic impact of clopidogrel based on
CREDO in Switzerland, Belgium, Italy, and France. METHODS:
We used clinical outcomes and resource use from CREDO com-
bined with external survival data to assess the long-term cost-
effectiveness of clopidogrel. A total of 2116 patients with
coronary artery disease were randomized to clopidogrel loading
before PCI plus one year therapy (n = 1053) vs. 28 days clopi-
dogrel followed by placebo (n = 1063). All patients received
clopidogrel day zero to 28. In all, 89 (8.45%) patients in 
the treatment arm and 122 (11.48%) in the placebo group 
had an event (RRR 26.9%, 95% CI 3.9%–44.4%). Hospital-
izations were assigned a Diagnostic Related Group (DRG)
through a DRG grouper. Unit costs were developed in each
country and applied to all patients of the CREDO study. Lost
life expectancy associated with death, MI and stoke was 
estimated from Saskatchewan data and discounted 3%. Cost
effectiveness was expressed as the cost per event avoided and as
cost per Life year saved (LYS). RESULTS: The cost effectiveness
of one year use of clopidogrel in addition to a clopidogrel load-
ing strategy prior to PCI vs. placebo ranges from 15,765€ to
26,074€/event prevented. The cost per LYS is 2483€/LYS in
Belgium, 2502€/LYS in France; 2552€/LYS in Italy; 2659€/LYS
in Switzerland based on Saskatchewan projection. CONCLU-
SION: Clopidogrel used prior to PCI and for one year thereafter
is a cost effective strategy. Consistent results are found in the
four countries studied.
CARDIOVASCULAR DISEASE—Arrhythmia
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OBJECTIVE: The objective of the study was to analyze annual
health resource utilization and costs of patients with atrial ﬂutter.
While the majority of atrial ﬂutter research has focused on
various pharmacologic, cardioversion, and catheter ablation
treatment options, the costs associated with treating atrial ﬂutter
patients have not been previously reported. METHODS: All
patients receiving a diagnosis of atrial ﬂutter (ICD-9 427.32)
between January 1, and December 31, 2002 were identiﬁed from
a nationally representative private payer database (IHCIS,
Waltham, MA). Patients <18 years of age or not continuously
enrolled in a health plan for one year following the atrial ﬂutter
diagnosis were removed from the analysis. Total one-year health
resource use and costs, including hospital inpatient, outpatient,
professional, ancillary, and pharmacy services, were measured
from a third-party payer perspective. RESULTS: The study
included 4945 patients with an atrial ﬂutter diagnosis. The
average age was 62 years; 65% were male. The top co-morbid
conditions were atrial ﬁbrillation (72.3%), hypertension (55%),
and neoplasms (27%). Average total one-year medical costs for
atrial ﬂutter patients were $25,652 +/-$44,814, of which inpa-
tient hospitalizations comprised almost 50% of the total cost.
Over half of patients were hospitalized with mean length of stay
of 6.78 +/-20.73 days, 83% had at least one outpatient visit,
while almost all patients had a physician visit and 71% required
at least one pharmacy visit during the one-year follow-up. 
